A medical laboratory technician works in a research lab in South Africa, February 14, 2025. REUTERS/Ihsaan Haffejee

UNIQURE NV shares plummeted 40% on Tuesday after four-year data for its Huntington's disease gene therapy fell short of the goal to slow progression. The drop follows the Netherlands-based biotech's application for approval in the United States.